If they have started the trials there would be a PR about it as that should be considered a material event. It involves cash transactions that affect the company's balance sheet.
But silence is supposedly golden. I don't understand why so many people think it's a bad thing. When you fly on a plane, you don't expect the pilot to tell you how everything is going every 15 minutes. That would be so annoying to all the passengers. It's the same thing with our CEO. It's not as if he hasn't been working since December. We've advanced the Rett trial to near-completion. We've signed a marketing partnership with an AI company. We're running an extended trial that may be sufficient for P4 confirmatory evidence. We're attending investor conferences and we're seeing an uptick in institutional ownership. Our CEO swapped cash for more shares, has assured us the overall data is worthy of FDA approval and has, for the first time, indicated that partnership discussions have occurred. Allegedly, Dr. Missling met with an investment bank per a report on TheFly, and who knows how many more he's taken in the years since -- that's the world he comes from so I doubt he's lacking in contacts.
I am fine investing my own money in Anavex. As confident and hopeful as I am, I would not feel comfortable risking anyone else's money. It's not investment grade, yet. If things pan out the way I hope and expect, one day it will be. And for that risk I expect to be rewarded for my patience, or punished for it. Time will tell. In the meantime, nothing posted here is going to change anyone's opinion. Only time will. And at the end of the day, the health insurance companies and the person who makes decisions for Medicare will be the ones who are ultimately responsible for deciding whether Blarcamesine becomes the next standard of care. FDA approval isn't the final hurdle. It's just the next big one.
News 
Market Data 
Discover 
AI
